Testing overall and subpopulation treatment effects with measurement errors by Ma, Y & Yin, G
Title Testing overall and subpopulation treatment effects withmeasurement errors
Author(s) Ma, Y; Yin, G
Citation Statistica Sinica, 2013, v. 23, p. 1019-1042
Issued Date 2013
URL http://hdl.handle.net/10722/189460
Rights Creative Commons: Attribution 3.0 Hong Kong License
Statistica Sinica 23 (2013), 1019-1042
doi:http://dx.doi.org/10.5705/ss.2012.049
TESTING OVERALL AND SUBPOPULATION TREATMENT
EFFECTS WITH MEASUREMENT ERRORS
Yanyuan Ma and Guosheng Yin
Texas A&M University and The University of Hong Kong
Abstract: There is a growing interest in the discovery of important predictors from
many potential biomarkers for therapeutic use. In particular, a biomarker has
predictive value for treatment if the treatment is only eective for patients whose
biomarker values exceed a certain threshold. However, biomarker expressions are
often subject to measurement errors, which may blur the biomarker's predictive
capability in patient classication and, as a consequence, may lead to inappropriate
treatment decisions. By taking into account the measurement errors, we propose
a new testing procedure for the overall and subpopulation treatment eects in the
multiple testing framework. The proposed method bypasses the permutation or
other resampling procedures that become computationally infeasible in the presence
of measurement errors. We conduct simulation studies to examine the performance
of the proposed method, and illustrate it with a data example.
Key words and phrases: Biomarker study, clinical trial, measurement error, multiple
testing, predictive marker, subgroup analysis, treatment eect.
1. Introduction
To a large extent, decisions on cancer treatment rely upon some specic
biomarkers of patients. Due to patient heterogeneity, even for those with the
same type of cancer and the same stage of disease, certain biomarkers may be
dierentially expressed which, in turn, may cause patients to respond dierently
to the same treatment. Most cancer treatments can be generally classied as
cytotoxic agents and cytostatic agents. Cytotoxic agents may benet patients
by directly destroying cancer cells, while cytostatic agents function through in-
hibiting tumor growth instead of shrinking the tumor. Targeted therapies are
typically cytostatic, and they may work only on a subset of the patient pop-
ulation with specic biomarker expression (Korn et al. (2001); Simon (2009);
and Ratain and Sargent (2009)). Hence, it is critical to detect the treatment
eect not only for the entire population, but also for a subpopulation identi-
ed by specic biomarkers. This is especially important in the development of
personalized medicine where the treatment is expected to work only for certain
subpopulations.
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We focus on biomarkers measured at the baseline that would provide in-
formation for better treatment decisions. According to their functionalities in
diagnosis and treatment selection for cancer patients, biomarkers are considered
therapeutically useful if they have prognostic or predictive values. Prognostic
markers reect patients' prognosis such as their health status or disease stages,
and they are associated with the disease outcome regardless of the presence of
treatment. Predictive markers can predict dierential treatment eects for pa-
tients belonging to dierent biomarker groups. In particular, these biomarkers
have the capability of predicting which group of patients, say either marker pos-
itive or marker negative, is more likely to benet from the treatment. Several
examples of prognostic and predictive biomarkers are described as follows. In
breast cancer, estrogen receptor (ER) overexpression may be used as a prognos-
tic marker because ER positive patients have longer survival in the absence of
systemic therapy. In addition, ER may also be used as a predictive marker be-
cause ER positive patients would benet from anti-estrogens such as tamoxifen,
and ER negativity predicts benets from some cytotoxic chemotherapies. Also
for breast cancer patients, the human epidermal growth factor receptor 2 (HER2)
amplication is a predictive marker for treatment benets from trastuzumab. In
colorectal cancer, patients with KRAS mutations appear to be poor candidates
for treatment with epidermal growth factor receptor (EGFR) antibodies. For
example, cetuximab and panitumumab only benet colorectal cancer patients
with the wild-type KRAS gene status, but not those with mutant KRAS.
In oncology, targeted therapies are often putative or tumor growth-inhibitory
agents. From the trial design perspective, the goal is to identify the subpopu-
lation of patients who would benet from the treatment (Sargent et al. (2005)).
Freidlin and Simon (2005) proposed an adaptive signature design to identify sen-
sitive patients through an assay or a signature (the gene-expression classier).
To enhance eciency of the adaptive signature design, Freidlin, Jiang, and Si-
mon (2010) proposed a cross-validation approach to combining the prospectively
developed sensitive patient classier and the properly powered test to maximize
the overall treatment eects. Suppose that we compare an experimental drug
with a control, and the experimental treatment only benets patients with a
high level of certain biomarker expression. Nevertheless, we have a continuous
measurement for the biomarker expression but no binary classier to categorize
patients into marker positive (the biomarker expression is higher than a thresh-
old), or marker negative (the biomarker expression is lower than a threshold)
groups. In this situation, Jiang, Freidlin, and Simon (2007) proposed two proce-
dures for hypothesis testing. Through subgroup analysis, they examined whether
the treatment eects are the same or greater in patients with a specic feature or
risk factor, so that subsequent marker-specic treatment decisions can be made.
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However, biomarker expressions are often measured with errors that prevent
us from classifying patients into marker positive or negative groups even if we
are given a specic threshold. As naive methods ignoring measurement errors
generally result in biased estimation, various methods have been developed to
correct such bias; see Carroll et al. (2006) for a comprehensive description. In
our case, the mismeasured biomarker value lies inside an indicator function, which
is used to identify the \sensitive" patients who would respond to the treatment.
Thus, it is in some sense related to measurement errors with change points, for
which the estimation and inference are known to be much more dicult than
the usual measurement error problems and, to our best knowledge, no approach
has been proposed beyond the linear regression context (Ma (2011)). In this
paper, we investigate the eects of measurement errors on the classication of
patients, propose consistent estimators to handle the measurement errors inside
the indicator function, and further develop hypothesis testing for both the entire
population and the subpopulations based on the mismeasured biomarker values.
The validity of our testing procedure does not require any resampling procedure
which may hamper the applicability of the test due to the high computational
cost.
The rest of the paper is organized as follows. In Section 2, we briey review
the two methods proposed by Jiang, Freidlin, and Simon (2007) that lay out
the general framework for identifying predictive biomarkers. In Section 3, we
investigate the situation where the biomarker values are measured with errors.
In particular, we propose a new hypothesis testing procedure and an ecient way
to estimate the cuto value for determining marker positive or marker negative
groups. In Section 4, we present a simulation study to evaluate the nite-sample
properties of the proposed method. We illustrate the new method using the
Framingham data in Section 5, and conclude with a brief discussion in Section
6. Technical details are delineated in the Appendix.
2. Identication of Predictive Biomarkers
From a statistical point of view, identication of predictive biomarkers or
similar studies along the line, can be formulated as a multiple testing problem.
For simplicity, we assume that the primary endpoint is binary; that is, Yi = 1
if patient i has responded to treatment, and Yi = 0 for a nonresponder. Let
Zi = 1 if patient i is treated with the experimental treatment, and Zi = 0 if the
subject is treated with the standard treatment; and let Xi denote the biomarker
expression. We model Yi with respect to both Zi and Xi via the generalized
linear model,
Pr(Yi = 1jXi; Zi) = G(1 + 2Xi + 3Zi); (2.1)
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where the link function may be logit G(u) = eu=(1 + eu), or probit (u), with
(u) denoting the cumulative distribution function of the standard normal dis-
tribution.
Model (2.1) characterizes the eectiveness of the overall treatment for all
the patients as reected by testing whether 3 is zero. However, the treatment
may work only for a subpopulation with biomarker expression satisfying Xi > c,
where c is an unknown cuto value, called a cutpoint of the biomarker. As a
result, we may t a more exible model,
Pr(Yi = 1jXi; Zi) = Gf1 + 2Xi + 3ZiI(Xi > c)g: (2.2)
Even if the treatment is not eective for all patients, it may still be eective
for a subset of patients whose biomarker values are larger than c, as reected
by 3 6= 0 in model (2.2). Without loss of generality, we assume that the range
of possible biomarker values is 0  c  1. When c = 0, model (2.2) reduces to
model (2.1). In the targeted therapy development, we need to determine whether
(i) 3 6= 0 in model (2.1),
(ii) 3 6= 0 in model (2.2) for at least one cutpoint c, and
(iii)3 = 0 in both (2.1) and (2.2).
Toward these goals, Jiang, Freidlin, and Simon (2007) proposed procedures A
and B that we outline as follows.
Procedure A splits the problem into two separate hypothesis tests. The rst
test concerns (2.1), with the null and alternative hypotheses given by
H0 : 3 = 0 versus H1 : 3 6= 0:
The second test concerns model (2.2), with the same null and alternative hy-
potheses. If the overall type I error rate is set at , a typical choice is to split 
in a ratio of 4:1 between the two tests, 1 = 0:8 for the rst test and 2 = 0:2
for the second. If the rst test rejects H0 at a signicance level of 1, the proce-
dure terminates and the treatment is deemed to be eective for all the patients
as in case (i). If the rst test fails to reject H0, the second test is subsequently
performed at a signicance level of 2. If the second test rejects H0, then the
treatment is deemed to be eective only for a subset of patients whose biomarker
expression levels exceed a certain cutpoint as in case (ii). If the second test also
fails to reject H0, then the treatment is considered ineective at all as in case
(iii). For the second hypothesis testing, we may construct a test statistic S(c)
for a given cutpoint c, and take the nal test statistic as TA = max0<c1 S(c).
Procedure B is more sophisticated. It aims at testing H0 : 3 = 0 for all c
in model (2.2) versus H1 : 3 6= 0 for at least one value of c. The test statistic is
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constructed as TB = maxfS(0) + R; max0<c1 S(c)g, where R is a prespecied
constant to upweigh the contribution of the overall treatment eect in order
to achieve a suitable balance. It is typically recommended that R = 2:2, the
dierence between the 95th and 80th percentiles of the chi-squared distribution
with one degree of freedom. IfH0 is not rejected, then the treatment is considered
to be ineective for any subgroup as in case (iii). If H0 is rejected, then the
treatment is considered to work for at least a subset of patients depending on
the value of c, while this subset of patients could also be the entire population if
c = 0.
In the second test of procedure A and in procedure B of Jiang, Freidlin, and
Simon (2007), the test statistics TA and TB take the maximum over a range of
values of c, and thus it is dicult to derive their asymptotic null distributions. As
outlined in the Appendix, a bootstrap-based procedure can be used to calculate
the p-value. If both cases (i) and (iii) are excluded in procedure A, or if case (iii)
is excluded in procedure B, the next step is to nd an appropriate cutpoint c, in
order to identify which subset of patients would be suitable for the treatment.




Gf^1(c) + ^2(c)Xi + ^3(c)ZiI(Xi > c)gYi
[1 Gf^1(c) + ^2(c)Xi + ^3(c)ZiI(Xi > c)g]1 Yi ;
where ^(c) = (^1(c); ^2(c); ^3(c))
T is the maximum likelihood estimator (MLE)
of  = (1; 2; 3)
T for a xed value of c.
3. Proposed Methods
3.1. Biomarkers with measurement errors
The procedures A and B in Jiang, Freidlin, and Simon (2007) are easy to
implement if the biomarker value can be measured precisely. However, it is known
that biomarker values are usually subject to measurement errors. Instead of
observing the true biomarker value Xi for subject i, we might observe a surrogate
value Wi = Xi + Ui, where Ui is the error incurred in the measurement of Xi.
Typically, Ui is assumed to follow a normal distribution with mean zero and
variance 2U . In practice, U can be estimated using repeated measurements or
validation observations; for simplicity we take U as known provisionally. Under
the assumption of normal measurement errors and a logit link function G(), we
can derive a consistent estimator for  by applying the conditional score method
to model (2.1). Specically, following Stefanski and Carroll (1987), for the rst
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test in procedure A, we have
nX
i=1




0@ 1Wi + Yi2U2
Zi
1A = 0:
Consequently, we can construct a Wald test statistic, and conduct hypothesis
testing at the desired signicance level 1 in a straightforward way. However, in
the presence of measurement errors, the second test of procedure A and the test in
procedure B are nontrivial because the covariate subject to measurement errors
lies inside an indicator function in model (2.2), and the traditional methods in
Carroll et al. (2006) are not directly applicable. Although regression calibration
(Carroll and Stefanski (1990) and Gleser (1990)) or SIMEX (Cook and Stefanski
(1995)) can still be used, these methods are approximate and typically do not
provide consistent estimation.
Following the semiparametric approach of Tsiatis and Ma (2004), we can
construct the estimating equation for  for a xed value of c,
nX
i=1
(Wi; Yi; Zi;) = 0;
where
(Wi; Yi; Zi;) = S

(Wi; Yi; Zi;)  Efa(Xi; Zi;)jWi; Yi; Zig
S(Wi; Yi; Zi;) = E
fSF (Xi; Yi; Zi;)jWi; Yi; Zig;
SF (Xi; Yi; Zi;) is the score function of the logistic model in (2.2), and a(Xi; Zi;)
satises
EfS(Wi; Yi; Zi;)jXi; Zig = E[Efa(Xi; Zi;)jWi; Yi; ZigjXi; Zi]:
The evaluation of expectation E(jWi; Yi; Zi) requires the probability density
function of Xi, which is not available. Our procedure replaces E(jWi; Yi; Zi)
with E(jWi; Yi; Zi), calculated under a proposal density function of Xi. The
proposal model could be misspecied, yet the resulting estimator is still consis-
tent due to the fact that
Ef(Wi; Yi; Zi;)g
= E[S(Wi; Yi; Zi;) Efa(Xi; Zi;)jWi; Yi; Zig]
= E
 
EfS(Wi; Yi; Zi;)jXi; Zig   E[Efa(Xi; Zi;)jWi; Yi; ZigjXi; Zi]

= 0:
In addition, the estimator ^ has a root-n rate and the asymptotic variance ofp






and B = Covf(Wi; Yi; Zi;)g:
MULTIPLE TESTING WITH MEASUREMENT ERRORS 1025
For a more elaborate description of estimating equation approaches to measure-
ment error models and sandwich variance estimation, see Tsiatis and Ma (2004).
Based on ^ and the estimated variance-covariance matrix V^, a Wald test
statistic may be constructed as S(c) = n^23(c)=V^33(c), where V^33(c) is the (3; 3)
entry of V^. We can further dene TA = max0<c1 S(c) for the second test in
procedure A or TB = maxfS(0) + R; max0<c1 S(c)g in procedure B. The p-
value can be calculated following the same bootstrap procedure as described in
the Appendix.
Although the adaption of the testing procedure A or B from the error-free
case to the measurement-error case is conceptually achievable, the computation is
extremely intense. For each xed cutpoint value c, we need to apply the Newton-
Raphson algorithm to estimate the parameter . Within each iteration of the
Newton-Raphson procedure, we must evaluate the estimating equation and its
derivative, which requires solving an integral equation to obtain the function
a(X;Z;). Since the lower and upper quantiles of the null distribution for the
test statistic are needed for hypothesis testing via the bootstrap, this in turn
increases the computational burden. In what follows, we develop a dierent
testing procedure based on the asymptotic distribution of a new test statistic
that alleviates the computational eort.
3.2. Hypothesis testing on subpopulations
In the implementation of procedure B of Jiang, Freidlin, and Simon (2007),
the test statistic is to be TK = maxfS(0) +R; maxc2;:::;cK S(c)g for a set of can-
didate values of c, c = fc1  0; c2; : : : ; cKg. The dierence between the original
TB and the implemented TK is that TB is based on all values of c continuously
for 0  c  1, and thus it is used to test no treatment eect at any value of c in
the range of [0; 1], while TK is used to test no treatment eect at a set of specic
values of c, namely c = fc1  0; c2; : : : ; cKg. We observe that in model (2.2) if
(and only if) the treatment is eective for the true cutpoint c0, it is eective for
any other cutpoint c. We illustrate this point. First, we consider that H1 : 3 6= 0
is true in a two-arm study. Note that in model (2.2) 1 represents the treatment
eect of the standard arm. Figure 1 shows that the intercept is indeed shifted
by 3 in the subset f(Xi; Zi) : Xi > c0 and Zi = 1g from its complementary
region, and the intercept of the set f(Xi; Zi) : Xi > c (c 6= c0); and Zi = 1g is
also shifted. As an illustration, suppose 3 > 0, and take c > c0. In this case, 1
calculated under c is larger than that obtained under c0, since it is inated by
the set f(Xi; Zi) : c > Xi > c0 and Zi = 1g, while it is still smaller than 1 + 3
because the eect of Xi > c and Zi = 1 does not contribute to the calculation
of 1. This means that 3, calculated under c, is still positive, although it is
smaller than that obtained under c0 as shown in the second plot of Figure 1. On
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the other hand, if we take c < c0, then the value of 1 remains the same under c
or under c0, while 3, calculated under c, would be smaller than that under c0,
because some of the \irrelevant" Xi values would also be considered \relevant",
and thus the treatment eect is diluted; see the third plot in Figure 1. Second, we
consider the case that H0 : 3 = 0 is true; so the treatment is not eective for any
cutpoint value of c, including those in the chosen set c = fc1 = 0; c2; : : : ; cKg.
Thus, using the candidate cutpoint set to form the test statistic still yields a
consistent testing procedure. The dierence between TB and TK is only reected
in statistical power; power would be less if we take the value of c to be dierent
from the true cutpoint value c0.
If there is no treatment eect, then there is no treatment eect for any
cutpoint value; so 3(c)  f3(c1); : : : ; 3(cK)gT = 0 for a chosen set of can-
didate cutpoint values fc1; : : : ; cKg. Specically, we can estimate 3(c) and
its variance-covariance matrix V3 using the method described in Section 3.
Based on the sample estimates ^3(c) and V^3, the test statistic is constructed
as T (c) = ^3(c)
TV^ 13 ^3(c), which is chi-squared with K degrees of freedom un-
der the null hypothesis. This new test becomes a standard hypothesis testing
problem that does not involve multiple comparisons. It allows us to compute the
p-value and conduct hypothesis testing without the need to resort to a bootstrap
procedure.
3.3. Estimation of biomarker cutpoint
If the test concludes that the treatment is eective for a subset of patients
with biomarker values satisfying X > c, the next step is to determine the cut-
point c. When the biomarker value is measured precisely, c can be estimated
by maximizing the prole likelihood. However, the same procedure cannot be
applied when X is measured with errors because the likelihood cannot be derived
without assuming a specic distribution for X. Instead, we can estimate c by






In fact, it is more convenient to use the score test statistic. For ease of exposition,
we denote the rst two components of  as a and the last component of  as





3(Wi; Zi; Yi; ea; 0; c);
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Figure 1. Illustration on the changes of the regression lines when a candidate
cutpoint instead of the true cutpoint is used under the alternative H1. The
top panel is based on the true cutpoint c0, the middle panel uses a candidate
cutpoint c > c0, and the bottom panel uses a candidate cutpoint c < c0.
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where ea is the estimator of a under the null hypothesis H0 : 3 = 0 in
model (2.2), so it does not depend on c. We denote the ith observation as















v(c) = Varf3(Oi;a0; 0; c) A2(c)A 11 a(Oi;a0; 0)g;
where a0 denotes the true value of a. For a xed value of c, these quantities
can be calculated by replacing expectations and covariance matrices with their
empirical counterparts and inserting the estimator ea. If we denote the estimate
of v(c) by v^(c), we can estimate c by maximizing U^2(c)=v^(c). In the Appendix,
we show that the variance of c^ can be estimated by ^2c = ^
 2dVar(i)=n; evaluated
at (ea; 0; c^), where  and i are given in (A.1) and (A.2), respectively. Both 
and i involve the rst or second derivative of 3 with respect to c. However, 3
is not a continuous function of c, which makes the variance estimation for the
cutpoint very dicult. This is similar to the situation encountered in quantile
regression, yet here the issue of discontinuity is more severe and we resort to a
bootstrap procedure to estimate the variance of c^.
After obtaining c^, we can proceed to estimate  using the semiparametric
estimation procedure described in Section 3. In addition to the original variance-
covariance matrix while assuming c xed, an extra source of variation should be
considered due to estimating c, and thus the variance-covariance matrix of ^(c^)
is estimated by








where c is evaluated at c^. Note that estimation of a cutpoint is a very dicult
problem due to the discontinuity caused by the indicator function. This is true
when the covariates are measured precisely, for example, see Luo, Turnbull, and
Clark (1997), Pons (2003), and Kosorok and Song (2007) for estimation of a
changepoint in survival models. The problem becomes even more challenging
when the covariates are measured with errors.
4. Simulation Study
We conducted extensive simulation studies to evaluate the performance of
the proposed estimation and testing procedure. The true parameter values were
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1 =  1:5 and 2 = 1:0 under the null model, and were 1 =  1:5, 2 = 1:5
and 3 = 1:0 with the true cutpoint c0 = 1:0 under the alternative model. The
covariate Xi was uniform on [0; 3], and the measurement error was normal with
a standard deviation of 0.1732, which corresponds to the noise-to-signal ratio of
20%. The sample size is typically large in these studies in order to identify a
responsive subset of subjects, as such a subset may be small, say, 20% or 30%
of the total population. We took sample sizes n = 500 and 1,000, and replicated
1,000 data sets.
In the implementation of the proposed estimation and testing procedure, we
posited the distribution of the true biomarker expression X to be either uniform,
normal, or exponential, corresponding to the true and two misspecied cases, re-
spectively. We took the set of candidate cutpoint values c = f0; 0:6; 1:2; 1:8; 2:4g
that does not include the true cutpoint c0 = 1:0. For comparison, we also present
simulation results using a naive approach, for which the measurement errors are
completely ignored. In the absence of measurement errors, the estimation pro-
cedure reduces to that of Jiang, Freidlin, and Simon (2007).
The upper panel of Table 1 summarizes the results for the type I error rate
and power. We can see that the proposed tests are generally consistent, as
reected by the closeness between the sample proportions of rejecting the null
hypothesis and the corresponding nominal levels. Even when f(x), the assumed
distribution ofX, is misspecied as a normal or exponential distribution, the type
I error rates are still maintained at the nominal levels. By contrast, the naive
testing procedure is severely biased, leading to an ination of the type I error
rate. Because the estimation variability is inevitably higher with measurement
errors, some power loss is incurred for the proposed method compared with its
naive counterpart. To gain more insight into the inuence of selection of the
candidate cutpoint set on power, we further explored the case that the true
cutpoint c0 = 1:0 happened to be included in the candidate set by taking the
candidate set c = f0; 0:6; 1:0; 1:8; 2:4g. Comparing the lower and upper panels of
Table 1, we can see that there is indeed some power loss when the true cutpoint
is not included in the candidate cutpoint set. However, the power loss is not
substantial, in general within the 5% dierence. This is certainly encouraging,
as the true cutpoint is never known in practice.
Tables 2 and 3 show the parameter estimates when the true cutpoint c0 is
not contained in the candidate set, with the sample size n = 500 and 1,000,
respectively. Clearly, the estimates using the naive method are biased which,
in turn, causes inconsistency of the naive testing procedure. The biases are
especially large for the intercept term under the null hypothesis, and for both
the intercept and slope terms under the alternative hypothesis. By contrast,
the proposed method provides consistent estimates of model parameters with
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Table 1. Levels of precision and power of the test with sample size n = 500
and 1; 000. The true cutpoint c0 is or is not included in the candidate set,
and the proposal distribution for the mismeasured covariate is uniform (the
true model), normal, and exponential, respectively.
Test size under H0 Power under H1
Nominal level 0.01 0.05 0.1 0.15 0.01 0.05 0.1 0.15
n = 500, c0 is not in the candidate set
Uniform f(x) 0.023 0.057 0.100 0.153 0.289 0.509 0.640 0.718
Normal f(x) 0.022 0.055 0.096 0.143 0.272 0.477 0.590 0.673
Exponential f(x) 0.023 0.055 0.099 0.149 0.281 0.517 0.635 0.711
Naive method 0.016 0.073 0.134 0.177 0.336 0.579 0.704 0.780
n = 1000, c0 is not in the candidate set
Uniform f(x) 0.009 0.053 0.099 0.139 0.600 0.809 0.881 0.931
Normal f(x) 0.009 0.050 0.098 0.134 0.589 0.787 0.862 0.908
Exponential f(x) 0.009 0.053 0.104 0.142 0.628 0.820 0.882 0.920
Naive method 0.018 0.070 0.135 0.191 0.777 0.914 0.959 0.972
n = 500, c0 is in the candidate set
Uniform f(x) 0.022 0.067 0.110 0.154 0.309 0.533 0.643 0.717
Normal f(x) 0.023 0.066 0.112 0.144 0.323 0.518 0.648 0.731
Exponential f(x) 0.020 0.067 0.117 0.170 0.311 0.533 0.648 0.731
Naive method 0.018 0.074 0.123 0.178 0.389 0.640 0.770 0.827
n = 1000, c0 is in the candidate set
Uniform f(x) 0.011 0.059 0.105 0.147 0.637 0.818 0.900 0.933
Normal f(x) 0.013 0.058 0.106 0.152 0.628 0.828 0.899 0.937
Exponential f(x) 0.014 0.064 0.109 0.155 0.662 0.859 0.913 0.942
Naive method 0.019 0.071 0.122 0.174 0.836 0.939 0.967 0.980
negligible biases. In addition, the standard errors for the estimates of  are
quite close to the standard deviations, and the coverage probabilities of the 95%
condence intervals are reasonably close to the nominal level. As the sample size
increases, the estimation, particularly that for 3, is much improved. For the
cutpoint c, the point estimate is consistent with small bias, while the variance is
often over-estimated because the estimation of c is extremely dicult due to the
discontinuity caused by the indicator function.
We further experimented the situations where the true cutpoint happened to
be included in the candidate set by considering the candidate set c = f0; 0:6; 1:0,
1:8; 2:4g, and repeated the simulations as before. Tables 4 and 5 correspond to
the results with sample sizes n = 500 and 1,000, respectively. The parameter
and variance estimates, as well as the coverage probabilities, are similar to those
when the candidate set does not contain the true cutpoint.
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Table 2. Parameter estimation with sample size n = 500 when the true
cutpoint c0 is not contained in the candidate set. The median of the pa-
rameter estimates is ^, the empirical standard deviation is SD, the median
of the estimated standard errors is SE, and the coverage probability of 95%
condence intervals is CP, in percentage.
Estimation under H0 Estimation under H1
True values 1 =  1:5 2 = 1:0 1 =  1:5 2 = 1:0 3 = 1:0 c = 1:0
Uniform f(x)
^  1.5057 1.0049  1.5062 0.9746 1.2494 1.0237
SD 0.1945 0.1454 0.2469 0.2708 0.4671 0.1766
SE 0.1871 0.1382 0.2529 0.2823 0.5353 0.2695
CP(%) 94.7 94.5 96.7 96.0 98.0 97.4
Normal f(x)
^  1.5057 1.0047  1.5105 0.9857 1.2125 1.0187
SD 0.1935 0.1452 0.2360 0.2668 0.4538 0.1746
SE 0.1871 0.1382 0.2541 0.2827 0.5339 0.2791
CP(%) 94.9 94.4 96.9 96.7 97.8 97.3
Exponential f(x)
^  1.5052 1.0045  1.4974 0.9736 1.2228 0.9879
SD 0.1935 0.1456 0.2412 0.2711 0.4486 0.1786
SE 0.1862 0.1373 0.2527 0.2799 0.5341 0.2783
CP(%) 94.9 94.2 95.9 96.4 97.6 98.4
Naive method
^  1.4523 0.9566  1.4116 0.8657 1.2862 1.0319
SD 0.1866 0.1372 0.2095 0.2214 0.3606 0.1292
SE 0.1808 0.1309 0.2235 0.2323 0.3879 0.2091
CP(%) 92.7 93.1 94.3 91.0 93.3 98.6
5. Example
We applied the proposed method to the data from the Framingham study.
This study contains 1,615 subjects, and the response of interest Y is the occur-
rence of coronary heart disease, a value of 1 or 0 indicating whether a subject
has the disease or is free of it. One of the study objectives is to characterize
how coronary heart disease is aected by the long-term average of systolic blood
pressure (covariate X). Based on the literature, it is known that X is subject to
an additive measurement error that is normally distributed with mean zero and
standard deviation 0.08 (Carroll et al. (2006)). Previous studies have established
that coronary heart disease is also related to smoking status (denoted as Z), in
that smokers are more likely to develop heart disease. We are interested in deter-
mining whether there is a \safe" zone for the blood pressure region in which, as
long as a subject's average blood pressure is below a certain threshold, smoking
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Table 3. Parameter estimation with sample size n = 1; 000 when the true
cutpoint c0 is not contained in the candidate set. The median of the pa-
rameter estimates is ^, the empirical standard deviation is SD, the median
of the estimated standard errors is SE, and the coverage probability of 95%
condence intervals is CP, in percentage.
Estimation under H0 Estimation under H1
True values 1 =  1:5 2 = 1:0 1 =  1:5 2 = 1:0 3 = 1:0 c = 1:0
Uniform f(x)
^  1.5053 1.0032  1.5074 0.9919 1.0881 0.9816
SD 0.1288 0.0955 0.1662 0.1844 0.2817 0.1529
SE 0.1316 0.0969 0.1759 0.1933 0.3035 0.2015
CP(%) 96.4 96.6 96.4 96.1 97.9 96.1
Normal f(x)
^  1.5048 1.0027  1.5098 0.9910 1.0871 0.9861
SD 0.1293 0.0958 0.1738 0.1908 0.2893 0.1596
SE 0.1316 0.0968 0.1759 0.1938 0.3038 0.2046
CP(%) 96.3 96.5 94.8 94.9 97.8 96.3
Exponential f(x)
^  1.5051 1.0029  1.5095 0.9938 1.0920 0.9594
SD 0.1287 0.0954 0.1678 0.1863 0.2851 0.1650
SE 0.1316 0.0968 0.1761 0.1945 0.3046 0.2037
CP(%) 96.4 96.7 96.5 97.0 97.8 96.5
Naive method
^  1.4524 0.9556  1.4208 0.8886 1.1520 1.0075
SD 0.1244 0.0905 0.1551 0.1570 0.2300 0.1198
SE 0.1273 0.0918 0.1569 0.1601 0.2500 0.1737
CP(%) 93.6 92.5 91.6 89.3 94.2 98.2
does not elevate the chance of developing heart disease. In other words, we aim
to identify a subpopulation based on the measurement of the blood pressure such
that the risk of developing heart disease for those subjects is not elevated even if
they smoke. This is particularly relevant for smokers trying to nd an \excuse"
for their smoking behavior. For the purposes of modeling, we can view smoking
behavior as a \treatment" indicator and blood pressure as a biomarker. If there
is such a subpopulation, we would be interested in nding the cutpoint on blood
pressure below which smoking does not make any dierence in the risk of heart
disease.
To implement our proposed procedure, we used ve (K = 5) candidate cut-
point values equally spaced along the supporting range of the observed blood
pressure values, 3:5528  W  5:2426, with the true blood pressure X unob-
served. Based on model (2.2), we obtained the test statistic T5 = 12:02, which
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Table 4. Parameter estimation with sample size n = 500 when the true
cutpoint c0 is contained in the candidate set. The median of the param-
eter estimates is ^, the empirical standard deviation is SD, the median of
the estimated standard errors is SE, and the coverage probability of 95%
condence intervals is CP, in percentage.
Estimation under H0 Estimation under H1
True values 1 =  1:5 2 = 1:0 1 =  1:5 2 = 1:0 3 = 1:0 c = 1:0
Uniform f(x)
^  1.5052 1.0043  1.5146 0.9931 1.2155 1.0200
SD 0.1957 0.1467 0.2462 0.2707 0.4748 0.1763
SE 0.1863 0.1373 0.2527 0.2825 0.5535 0.2763
CP(%) 94.5 94.3 95.6 96.3 97.6 97.4
Normal f(x)
^  1.5052 1.0040  1.5012 0.9746 1.2420 1.0217
SD 0.1941 0.1463 0.2283 0.2565 0.4580 0.1794
SE 0.1861 0.1373 0.2516 0.2796 0.5284 0.2624
CP(%) 94.8 94.6 97.2 97.6 98.0 98.1
Exponential f(x)
^  1.5063 1.0054  1.4974 0.9736 1.2228 0.9879
SD 0.1938 0.1454 0.2412 0.2711 0.4486 0.1786
SE 0.1863 0.1374 0.2527 0.2799 0.5341 0.2783
CP(%) 94.8 94.3 95.9 96.4 97.6 98.4
Naive method
^  1.4519 0.9562  1.3984 0.8524 1.2952 1.0302
SD 0.1887 0.1387 0.2117 0.2211 0.3398 0.1224
SE 0.1800 0.1300 0.2203 0.2297 0.3824 0.2043
CP(%) 92.5 92.7 93.1 90.6 94.2 98.7
exceeds the critical constant 11.07, the 95th percentile of the chi-squared distri-
bution with ve degrees of freedom. As a result, we reject the null hypothesis and
conclude that there exists a cutpoint on the blood pressure, above which smoking
has an eect on the development of heart disease. We further performed esti-
mation under the alternative model in (2.2) and obtained the estimates of the
regression coecients 1 =  14:69, 2 = 2:68, and 3 = 0:53, with the corre-
sponding estimated variances 3:49, 0:170, and 0:0636. The cutpoint is estimated
as c^ = 3:1, which is to the left of the entire region of the observed blood pressure
[3:5528; 5:2426]. We emphasize here that whether c^ is also to the left of the region
of the true blood pressure is unknown because X is not observed. Nevertheless,
our nding indicates that although smoking status has an eect only in the re-
gion above the cutpoint c^ = 3:1, this region contains all the observed values of
blood pressure. Hence there is indeed no \safe" zone in terms of the observed
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Table 5. Parameter estimation with sample size n = 1; 000 when the true
cutpoint c0 is contained in the candidate set. The median of the param-
eter estimates is ^, the empirical standard deviation is SD, the median of
the estimated standard errors is SE, and the coverage probability of 95%
condence intervals is CP, in percentage.
Estimation under H0 Estimation under H1
True values 1 =  1:5 2 = 1:0 1 =  1:5 2 = 1:0 3 = 1:0 c = 1:0
Uniform f(x)
^  1.5048 1.0027  1.5125 0.9986 1.0837 0.9919
SD 0.1292 0.0957 0.1698 0.1899 0.2978 0.1524
SE 0.1316 0.0968 0.1759 0.1944 0.3054 0.2001
CP(%) 96.3 96.5 96.1 95.6 96.8 95.7
Normal f(x)
^  1.5045 1.0021  1.5081 0.9892 1.0955 0.9926
SD 0.1291 0.0957 0.1756 0.1925 0.2851 0.1577
SE 0.1316 0.0968 0.1761 0.1942 0.3067 0.2066
CP(%) 96.3 96.5 94.8 95.5 98.6 96.3
Exponential f(x)
^  1.5050 1.0030  1.5095 0.9938 1.0920 0.9594
SD 0.1280 0.0951 0.1678 0.1863 0.2851 0.1650
SE 0.1317 0.0968 0.1761 0.1945 0.3046 0.2037
CP(%) 96.4 96.8 96.5 97.0 97.8 96.5
Naive method
^  1.4517 0.9546  1.4192 0.8865 1.1600 1.0126
SD 0.1246 0.0908 0.1566 0.1597 0.2247 0.1175
SE 0.1273 0.0918 0.1562 0.1601 0.2509 0.1710
CP(%) 93.6 92.3 91.2 89.0 94.0 97.8
blood pressure levels for smoking. This is important information to motivate all
smokers to quit smoking.
6. Discussion
We have developed a new testing procedure for treatment eects in either
an overall population or a subpopulation identied by some biomarker that may
be measured with errors. The proposed method diers from that of Jiang, Frei-
dlin, and Simon (2007) in three important aspects. First, our testing procedure
does not require the estimation of the true cutpoint c0. Instead, it requires one
to prespecify a set of candidate cutpoints and to construct a Wald test statistic.
Second, the p-value can be calculated based on the asymptotic distribution of the
test statistic, in contrast to using a bootstrap procedure that is computationally
infeasible in the presence of measurement errors. Third, due to the diculty
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in constructing a likelihood in measurement error models, we propose to maxi-
mize the score-type statistic to estimate the cutpoint instead of using the prole
likelihood approach.
One of the most interesting discoveries is that whether the set of candidate
cutpoints contains the true cutpoint or not, the test remains consistent, and the
power of detecting the treatment eect tends to one as the sample size increases.
This is a direct consequence of the root-n rate of the estimation procedure in
Section 3. However, in practice the selection of the candidate cutpoints has an
impact on power. This means that if the alternative model holds, a properly
chosen set can increase the power. In the ideal case, the best candidate set is
the one that contains only the true cutpoint c0. Of course the true cutpoint
is unknown, hence we suggest including several reasonable cutpoints in the set
based on scientic knowledge. When no such scientic information is available,
a natural choice is to include a series of equally spaced candidate cutpoints. Al-
though choosing more candidate cutpoints can increase the chance of capturing
the true one and thus improve power, it also results in a larger number of degrees
of freedom for the chi-squared test and thus diminishes power. Hence there is a
delicate balance in choosing the number of cutpoints. In order to capture the po-
tential global treatment eect, we suggest always including the lower limit of the
range ofW in the set of cutpoints. But we generally do not recommend including
the upper limit of the range of W , because it can cause degeneration of model
(2.2) if the upper limit point happens to lie out of the range of X. Based on
our experience, choosing between two to ve candidate cutpoints generally works
well. However, establishing a theoretically justiable method for the choice of
candidate cutpoints requires more research involving higher order asymptotic
properties. Finally, although the procedure is motivated from handling measure-
ment errors, the proposed method is certainly applicable when biomarkers are
measured precisely.
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Appendix
A.1. Bootstrap approximation of the p-value
Because the test statistic in Jiang, Freidlin, and Simon (2007) is constructed
as TA=max0<c1 S(c) in procedure A and as TB=maxfS(0)+R;max0<c1 S(c)g
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in procedure B, the asymptotic distributions of TA and TB under H0 cannot be
obtained easily. A bootstrap procedure can be used to determine the p-value in
this case. Specically, we randomly permute the Z1; : : : ; Zn values to the pairs
(X1; Y1); : : : ; (Xn; Yn) to form a new data set f(X1; Y1; Zb;1); : : : ; (Xn; Yn; Zb;n)g,
and then construct the same test statistic T b . Repeating the procedure a large





T )=B. Because the procedure to generate the data under the null hypothesis is
permutation-based, the resulting bootstrap test is also called the permutation
test.
A.2. Variance estimation of the cutpoint
Maximizing U^(c)2=v^(c) to estimate c is equivalent to solving
2U^ 0(c)v^(c)  U^(c)v^0(c) = 0;
where U^ 0(c) and v^0(c) correspond to the derivatives of U^(c) and v^(c) with re-
spect to c. Denote the maximizer of U^(c)2=v^(c) as c^, and let 03c(Oi;a; 0; c) =
@3(Oi;a; 0; c)=@c. We assume that c0 satises
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03c(Oi; ea; 0; c^)  03c(Oi;a0; 0; c0)o :
We now consider each term of the above equation separately. First, take
b(Oi;a; 0; c) = 3(Oi;a; 0; c) A2(c)A 11 a(Oi;a; 0);
MULTIPLE TESTING WITH MEASUREMENT ERRORS 1037






3(Oi; ea; 0; c^)  3(Oi;a0; 0; c0)o

























n(c^  c0) + op(1):

















=E f3(Oi;a0; 0; c0)g v00(c0)
p














b(Oi;a0; 0; c0)0bc(Oi;a0; 0; c0)
 E
n


























b(Oi;a0; 0; c0)0bc(Oi;a0; 0; c0)
 E
n













1038 YANYUAN MA AND GUOSHENG YIN















b(Oi;a0; 0; c0)0bc(Oi;a0; 0; c0)







[3(Oi;a0; 0; c0) E f3(Oi;a0; 0; c0)g]
















= E f3(Oi;a0; 0; c0)g v00(c0)
p






b(Oi;a0; 0; c0)0bc(Oi;a0; 0; c0)
 E b(Oi;a0; 0; c0)0bc(Oi;a0; 0; c0)	 i







[3(Oi;a0; 0; c0)  E f3(Oi;a0; 0; c0)g]

















03c(Oi; ea; 0; c^)
= 2
p








= [2fv0(c0) + op(1)g
p






















































[3(Oi;a0; 0; c0) Ef3(Oi;a0; 0; c0)g]+op(1);
































f3(Oi;a0; 0; c0) E3(Oi;a0; 0; c0)g+ op(1):






























n(c^  c0) + op(1);
where 003cc(Oi;a; 0; c) = @03c(Oi;a; 0; c)=@c.






















+E f3(Oi;a0; 0; c0)g v00(c0)
p





[b(Oi;a0; 0; c0)0bc(Oi;a0; 0; c0)
 Efb(Oi;a0; 0; c0)0bc(Oi;a0; 0; c0)g]






[3(Oi;a0; 0; c0)  E f3(Oi;a0; 0; c0)g]











 2E 03c(Oi;a0; 0; c0)	 v0(c0)pn(c^  c0)





























n(c^  c0) + op(1):
Let









MULTIPLE TESTING WITH MEASUREMENT ERRORS 1041
i = 3(Oi;a0; 0; c0)v0(c0)  203c(Oi;a0; 0; c0)v(c0)
 v0(c0)A2(c0)A 11 a(Oi;a0; 0)
+2E f3(Oi;a0; 0; c0)g [b(Oi;a0; 0; c0)0bc(Oi;a0; 0; c0)
 Efb(Oi;a0; 0; c0)0bc(Oi;a0; 0; c0)g]
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+4Ef03c(Oi;a0; 0; c0)gEf3(Oi;a0; 0; c0)gf3(Oi;a0; 0; c0)
 E3(Oi;a0; 0; c0)g+ 2v(c0)A02(c0)A 11 a(Oi;a0; 0): (A.2)
This yields





Hence, the variance of c^ can be estimated by the sample version ^2c = ^
 2dVar(i)=n
evaluated at (ea; 0; c^).
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